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Abstract
Background: To identify factors that predict low bone mineral density (BMD) in pediatric patients referred for
dual-energy x-ray absorptiometry assessments.
Methods: This is a retrospective cohort study of 304 children and adolescents referred for dual-energy x-ray
absorptiometry assessments at a tertiary care center. Outcomes included risk factors which predicted a significant
low bone density for age, defined as BMD Z-score ≤-2.0 SD. A univariate analysis involved Chi-square, Fisher’s Exact
test, and analysis of variance, and multivariate logistic regression models were constructed to determine predictors
of low bone mineral density.
Results: In the multivariate logistic regression model, predictors of low bone mineral density included low body mass
index Z-score (odds ratio 0.52, 95% confidence interval 0.39 – 0.69), low height Z-score (OR 0.71, 95% CI 0.57 – 0.88),
vitamin D insufficiency (OR 3.97, 95% CI 2.08 – 7.59), and history of bone marrow transplant (OR 5.78, 95% CI 1.00 – 33.45).
Conclusions: Underlying health problems and associated treatments can impair bone mineral accrual. We identified risk
factors most predictive of low bone mineral density in subjects referred for bone density measurement. Recognition of
these factors may allow for earlier assessment to maximize bone mass in at-risk children.
Keywords: Bone health, Low bone mineral density, Chronic disease, Vitamin D, Dual X-ray absorptiometry
Background
In 2010, the Boston Children’s Hospital Program for
Patient Safety and Quality convened a Task Force to
identify the frequency of fragility or insufficiency frac-
tures in hospitalized infants, children and adolescents
and to reduce the risk of these fractures. As low bone
density has been identified as a risk factor for fractures
in children [1,2] a component of this bone health safety
initiative was to identify factors associated with low bone
mineral density in patients seen in our institution.
Specific pediatric populations are known to be at high
risk for a low bone density, including children and ado-
lescents with cerebral palsy and other non-ambulatory
states [1-4], chronic renal failure [5], malnutrition and
malabsorptive states [6-8], cystic fibrosis [9-11], pubertal
delay [12], and 25-hydroxyvitamin D (25OHD) defi-
ciency [13,14]. In addition, medical therapies such as
treatment with anticonvulsants [15], glucocorticoids
[15], and chemotherapy [16,17] are associated with a
compromise of bone density. As fracture risk in children is
inversely related to bone density in some reports [18-22],
understanding the risk factors associated with low bone
mineral density may provide greater opportunities for early
identification and intervention for those at risk for skeletal
fragility. To our knowledge, no study has examined the
relative risk of these conditions and treatments on low
bone density in a pediatric population.
Dual-energy x-ray absorptiometry (DXA) is a common
methodology used to quantify bone mineral density
(BMD), and provides a measure of bone mineral (g) per
projected area scanned (cm
2). In children, a Z-score is
used to compare a child’s BMD with an age- and
gender-matched norm, with appropriate adjustments for
bone age or pubertal status often needed [20]. Guide-
lines established by the International Society for Clinical
Densitometry define a low bone density as a BMD Z-
score of less than or equal to -2.0 SD [23].
The objectives of this study were to determine risk fac-
tors for low bone density (BMD Z-score ≤ -2) in a
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have the strongest correlation with BMD. A secondary
aim was to examine whether fracture history was corre-
lated with BMD Z-scores in children and adolescents
who are within designated risk groups for low bone
density.
Methods
Subjects
We identified all patients between the ages of 4-21 years
who were referred to the Bone Health Program at Chil-
dren’s Hospital Boston for BMD measurements by DXA
as part of routine clinical care from October 2008 to
September 2009. Patients who had the DXA performed
as part of a research study were excluded. Subjects were
categorized based on their lowest BMD Z-score and
divided into three groups: BMD Z-score >-1.0 SD, be-
tween -1 to -1.9 SD, or≤ -2.0 SD. Based on the results of
a power analysis (described in ‘Statistical Analysis’), we
reviewed charts consecutively by scanning date until we
identified 100 subjects in each of the three subgroups
(532 charts reviewed). Once 100 subjects were identified
in a group, additional subjects in that group were not
included. The Boston Children’s Hospital Committee on
Clinical Investigation approved this protocol.
Densitometry measurements
Scans were performed on a single densitometer. Areal
(two-dimensional) bone density was quantified by DXA
using a Hologic Discovery A scanner [Hologic Inc,
Bedford, MA]. Bone mineral density (BMD, g/cm
2) mea-
surements were obtained at the left total hip and lumbar
spine (L1-L4), and in some cases, at the whole body.
Pediatric normative data were used to calculate BMD Z-
scores at each skeletal site [24] using pediatric software,
to allow for comparison with age- and gender-matched
controls [24]. With this instrument in our DXA Center,
the average in vivo precision for aBMD (expressed as
percent coefficient of variation) was 0.62% at the spine
and 0.72% at the total hip in children and adolescents.
Data collection
Height and weight were obtained using a calibrated sta-
diometer (Kalamazoo, MO) and scale. Body mass index
(BMI) was expressed as body weight in kilograms
divided by the square of height in meters (kg/m
2)a sa
weight-for-height index and was converted to percentiles
and corresponding Z-scores by using age- and gender-
specific normative values for US children [25]. We used
the normative values for maximal age (20 years) [25] to
calculate BMI for older subjects. Underweight was
defined as BMI <5
th percentile and overweight was
defined as BMI >85
th percentile for age and gender.
Demographic and medical history data and DXA reports
were obtained through a retrospective chart review of
the Boston Children’s Hospital medical record. Data
were collected from outpatient clinic notes, radiology
reports, and DXA reports. Data included ethnicity, gen-
der, fracture history, age at menarche, history of 25OHD
insufficiency (defined as 25OHD level <30 ng/mL, the
lower limit of the normal range for our clinical labora-
tory), family history of osteoporosis, and history of pre-
maturity. We recorded 25OHD values for subjects with
25OHD insufficiency. Information about specific med-
ical conditions and treatments was collected from the
medical record.
Data recorded from each subject’s DXA report
included the absolute BMD and corresponding Z-scores
at the left total proximal hip and lumbar spine (L1-L4).
Only selected patients had total body DXA measure-
ments, as the DXA measurements for many patients
within this sample were performed prior to published
recommendations by pediatric experts regarding pre-
ferred skeletal sites [23]. When available, DXA measure-
ments adjusted for bone age were recorded when bone
age differed significantly from chronological age. Add-
itional data collected from the DXA report included the
date of the study, the subject’s age, height, and weight at
time of the BMD measurements, the indication(s) for
the scan as provided by the referring physician, and the
total number of prior DXA scans the subject had
undergone.
Statistical analysis
A two proportion power analysis was used to determine
the minimum number of cases and controls necessary to
detect a 15 percentage point difference in risk factors
associated with low BMD Z-score (power=0.8, alpha=
0.05). We determined that a minimum of 100 cases (BMD
Z-score≤-2) and 200 controls (BMD Z-score>-2) would
give our study the power necessary to detect this differ-
ence. For the descriptive analysis, patients were stratified
into three groups based on the patient’s lowest BMD Z-
score (for multiple DXA readings): > -1.0 SD, between -1
to -1.9 SD, or≤-2.0 SD. Patient demographics among the
BMD Z-score groups were summarized using means and
standard deviations for continuous variables and propor-
tions for categorical variables. Statistical differences across
the three groups were analyzed using Pearson’s chi-square
or Fisher’s Exact test for categorical variables and one way
analysis of variance (ANOVA) for continuous variables.
Additionally, we assessed differences across DXA indica-
tions by gender using Pearson’s chi-square or Fisher’s
Exact test for categorical variables.
For the univariate analysis, we dichotomized the BMD
Z-scores into two groups: ≤ -2 and> -2 and assessed in-
dividual factors that may be associated with low BMD
Z-score. Pearson’s chi-square and Fisher’s Exact test
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used for continuous variables. Variables in the univariate
model with a p-value ≤ 0.05 were considered for inclu-
sion in a multivariate logistic regression model. A gender
specific sub-analysis looking at fracture history and low
BMD was performed using the Pearson’s chi-square test
and ANOVA to assess differences between BMD groups.
All analyses were performed using SAS software version
9.2 (SAS Institute Inc, Cary, NC), and a 2-sided p value≤
0.05 was considered indicative of statistical significance.
Results
We obtained information on 304 children and young
adults between the ages of 4-21 years old who under-
went DXA scans at Boston Children’s Hospital. Height
and weight measurements were available for 282 sub-
jects. Subject characteristics at the time of the DXA
scans are presented in Table 1, classified by BMD Z-
score. Of note, there were differences among the mean
age in each group, with a rise in mean age correlating
with increasing BMD Z-scores (p <0.01). We did not
identify differences between BMD Z-scores and race or
ethnicity, with more than 80% of subjects in our sample
self-identifying as white (p=0.40). BMI was significantly
different between the groups, with the lowest BMD
group having the lowest BMI Z-scores (p<0.001). Fif-
teen percent of underweight children and young adults,
defined as those with a BMI <5
th percentile for age and
gender, had a BMD Z-score≤ -2, while only 3% of
those with BMD Z-score> -1 were underweight (p<
0.01). We also found significant differences in height
Z-scores between the groups, with the lowest BMD group
having the lowest height Z-scores (p<0.001). As expected
based upon the study design, the mean hip and spine Z-
scores were significantly different between the groups (p<
0.001). In our sample population, we also identified that
male gender was associated with a BMD Z-score≤-2 (p=
0.01).
Indications for DXA, as documented on the DXA re-
port form from the referring provider, are presented in
Table 2. Providers had the option of selecting multiple
indications if applicable. We looked at differences in in-
dication by gender, and found that a slightly higher
percentage of males were referred for a history of frac-
ture, compared to females (p= 0.05). Additionally, a
greater percentage of males reported a history of
gastrointestinal disease (p<0.01), while a greater per-
centage of females had a history of hypogonadism (p <
0.001). Furthermore, as detailed in the univariate ana-
lysis (Table 3), report of a history of a chronic disease
associated with bone loss was predictive of a BMD Z-
score≤ -2 (p<0.001).
In the univariate analysis of factors associated with
BMD Z-score ≤-2 (Table 3), we found that correlates of
low BMD included low BMI Z-score for age and gender,
a history of fracture, a history of 25OHD insufficiency
Table 1 Characteristics of study subjects at time of DXA
Characteristic BMD Z-score≤- 2 - 2< BMD Z-score<-1 BMD Z-score≥-1 p
N =102 N= 101 N=101
Female 56 (55%) 63 (62%) 76 (75%) 0.009
Age (years) Mean±SD 13.6±4.1 14.5±4.3 15.5±3.3 0.003
Race/Ethnicity 0.397
White 88 (86%) 79 (78%) 83 (82%)
Black 1 (1%) 2 (2%) 4 (4%)
Hispanic 1 (1%) 4 (4%) 3 (3%)
Asian 2 (2%) 4 (4%) 3 (3%)
Other 6 (6%) 2 (2%) 3 (3%)
Not Documented 4 (4%) 10 (10%) 5 (5%)
BMI Mean±SD 18.8±3.6 20.2±4.4 23.1±5.2 <0.001
Underweight 13 (15%) 9 (9%) 3 (3%) 0.003
Healthy weight 62 (72%) 75 (76%) 65 (67%)
Overweight 9 (11%) 6 (6%) 16 (17%)
Obese 2 (2%) 9 (9%) 13 (13%)
BMI Z-score Mean±SD −0.43+ 1.0 −0.11+1.2 0.52+1.0 <0.001
Height Z-score Mean±SD −1.2±1.5 −0.7±1.3 −0.1 +1.1 <0.001
Hip Z-score Mean±SD −2.18± 1.1 −1.0±0.6 0.45±0.8 <0.001
Spine Z-score Mean±SD −2.4±0.9 −1.1±0.6 0.30±0.9 <0.001
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found that female subjects who had not reached menar-
che at the time of the DXA assessment were at increased
risk of low BMD, while amenorrhea was not identified
as a risk factor. For young women who had reached
menarche, there was no difference in average age of me-
narche between the two groups (13.1 ±1.6 years v. 12.8
±1.8, p= 0.646).
Medical diagnoses associated with low BMD included
cerebral palsy or non-ambulatory state, a history of
Table 2 Differences in indication for DXA by gender
Indication Male Female p
N = 109 N= 195
Medical History of Fracture 47 (43.1%) 62 (31.8%) 0.05
History of gastrointestinal disease* 35 (32.1%) 32 (16.4%) <0.01
Osteopenia noted on a prior x-ray 9 (8.3%) 21 (10.8%) 0.48
Hypogonadism or delayed puberty 6 (5.5%) 77 (39.5%) <0.001
Chronic disease associated with bone loss 41 (37.6%) 56 (28.7%) 0.11
*Includes inflammatory bowel disease, celiac disease, and malabsorption.
Table 3 Univariate analysis: Factors associated with BMD Z-score ≤ -2
Factor ≤ - 2 BMD Z-score BMD Z-score > - 2 p
N = 102 N= 202
Indication for DXA (reported on referral form)
Gastrointestinal disease* 14 (13.7%) 53 (26.2%) 0.013
Osteopenia noted on a prior x-ray 13 (12.8%) 17 (8.4%) 0.232
Hypogonadism or delayed puberty 23 (22.6%) 60 (29.7%) 0.186
Chronic disease associated with bone loss 51 (50.0%) 46 (22.8%) <0.001
Risk Factors
25OHD insufficiency (< 30 ng/mL) 68 (66.7%) 91 (45.1%) <0.001
Family history of osteoporosis 23 (22.6%) 26 (12.9%) 0.009
Has reached menarche (females only) 26 (47.3%) 95 (68.4%) 0.012
Amenorrhea (females only) 12 (35.3%) 53 (51.5%) 0.257
Delayed puberty (males only) 5 (10.9%) 5 (7.8%) 0.649
Fracture History** 42 (42.4%) 62 (31.0%) 0.051
Eating disorder 8 (7.8%) 26 (12.9%) 0.189
Cerebral palsy and/or non-ambulatory 22 (21.6%) 4 (2.0%) <0.001
Cystic fibrosis 6 (5.9%) 7 (3.5%) 0.371
Malnutrition § 17 (16.7%) 26 (12.9%) 0.370
Malabsorption or IBD 17 (16.7%) 64 (31.7%) 0.005
Osteogenisis imperfecta 3 (2.9%) 2 (0.99%) 0.339
Recipient of an organ transplant 5 (4.9%) 2 (1.0%) 0.032
Prior treatment with radiation and/or chemotherapy 8 (7.8%) 11 (5.5%) 0.415
Recipient of a bone marrow transplant 7 (6.9%) 2 (1.0%) 0.008
Glucocorticoid use ( > 2 weeks) 39 (38.2%) 74 (36.6%) 0.785
Anticonvulsant use 19 (18.6%) 13 (6.4%) 0.001
History of prematurity ‡ 9 (8.8%) 10 (4.9%) 0.022
Height z score (Mean + SD) -1.15 + 1.5 -0.37 + 1.2 <0.001
BMI z score (Mean + SD) -0.4 + 1.1 0.2 + 1.1 <0.001
*Includes inflammatory bowel disease, celiac disease, and malabsorption.
**Excludes patients with Osteogenisis Imperfecta (N=5).
§ Based upon clinical assessment by a nutritionist or physician, as documented in medical record.
‡ Gestational age < 36 weeks.
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anticonvulsants, and a history of prematurity, defined
herein as gestational age <36 weeks (all at p<0.05). We
did not find a difference (p=0.27) in duration of anti-
convulsant use between subjects with BMD Z-score≤ -2
(67.9 ±53.5 months) and those with Z-score >-2 (45.7±
45.1 months). Our sample size was too small to analyze
the associations between specific anticonvulsants and
low BMD. Unexpectedly, both report of a history of a
gastrointestinal disease as an indication for DXA (p<0.01)
and history of malabsorption or inflammatory bowel dis-
ease (p<0.01) were associated with a normal BMD.
For all subjects with a fracture history, we did not find
a difference (p=0.63) in mean fracture number between
those with BMD Z-score≤ -2 (3.0 ±5.0) and those with
Z-scores>- 2 (2.7 ±2.9). We also examined whether the
relation between low BMD and fracture history was
modified by gender, and found that a history of fracture
was associated with an increased risk of a low BMD for
males (p <0.01), but not for females (p=0.95) (data not
shown).
All of the patients with osteogenesis imperfecta (OI) in
our cohort were actively treated with bisphosphonates.
As a result of bisphosphonate treatment, some subjects
with OI had BMD Z-scores that exceeded -2 SD. Add-
itionally, the 5 patients with OI included in this study all
had sustained multiple fractures. Since bisphosphonate
treatment improves bone density [26-28], we excluded
the 5 patients with OI and repeated our univariate ana-
lysis to assess the impact of these patients on our results.
Without the children with OI, fracture history still
remained a risk factor for BMD Z-score ≤ -2 SD only for
boys (p=0.01).
As fracture risk may increase as the BMD Z-score falls
below -1 [18], we sought to identify factors associated
with this BMD threshold as well. Similar to our initial
univariate analysis, BMI <5
th percentile remained a pre-
dictor of low BMD. Additionally, a history of cerebral
palsy or non-ambulatory state and history of BMT were
associated with BMD Z-score<-1.
As there is uncertainty in characterizing (25OHD)
values between 20-30 ng/mL, we considered both of
these values in assessing for vitamin D insufficiency. For
subjects with 25OHD <30 ng/mL, we did not find a dif-
ference (p=0.24) between mean 25OHD measurements
in those with BMD Z-score≤-2 (19.3±6.9 ng/mL, n=67)
and those with Z-score>-2 (21.6±14.6 ng/mL, n=90).
44.8% of subjects with BMD Z-score≤-2 and 41.1% of
those with Z-score>-2 had a 25OHD measurement<
20 mg/mL, while 66.7% of subjects with BMD Z-score≤-
2 and 45.1% of those with Z-score>-2 had a 25OHD
measurement<30 mg/mL.
A multivariable logistic regression model was con-
structed to examine factors associated with a BMD Z-
score ≤-2 (Table 4). Significant predictors include low
BMI Z-score, low height Z-score, a 25OHD measure-
ment <30 ng/mL, and history of a BMT. BMI Z-score
was inversely related to the risk of low BMD, with an
odds ratio (OR) of 0.52 (95% confidence interval (CI)
0.39 – 0.69). Height Z-score was also inversely related to
the risk of low BMD (OR 0.71, CI 0.57, 0.88). We found
a notable clinical association between history of 25OHD
insufficiency and low BMD, with an almost 4-fold
increased risk of low BMD (OR 3.97, CI 2.08, 7.59). In
comparison, a history of BMT led to a nearly 6-fold
increased risk of low BMD (OR 5.78, CI 1.00, 33.45).
Table 4 Multivariate analysis: Risk factors associated with BMD Z-score ≤ -2
Factor Odds ratio (95% CI) p
BMI z-score <0.001
1 unit increase 0.52 (0.39, 0.69)
Height z-score 0.002
1 unit increase 0.71 (0.57, 0.88)
Vitamin D Insufficiency <0.001
Yes 3.97 (2.08, 7.59)
Not Documented/No 1.00
Malabsorption or IBD 0.001
Yes 0.29 (0.14, 0.60)
No 1.00
Recipient of a bone marrow transplant 0.050
Yes 5.78 (1.00, 33.45)
No 1.00
BMD Z-score ≤ -2, N = 86; BMD Z-score > -2, N = 196.
c statistic for model = 0.789.
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sorption or IBD was found to be associated with a nor-
mal BMD Z-score in the multivariate analysis. There
were no interactions among predictors in the final
model. The c-statistic, used to assess the predictive val-
idity of the model, was 0.789.
Discussion
Multiple underlying health problems and associated
treatments can impair bone mineral accrual during
childhood and adolescence. We sought to identify the
risk factors associated with low bone density in subjects
referred for DXA measurements of BMD at a tertiary
care pediatric hospital to help inform a bone health pa-
tient safety initiative. Using a multivariable logistic re-
gression model, we found that low BMI Z-score, history
of BMT, and 25OHD insufficiency were the medical
conditions most predictive of a BMD Z-score ≤-2, a
threshold deemed by expert consensus to represent a
significant low bone density for age [23].
We identified that history of BMT significantly
increases the risk of low BMD. Multiple mechanisms
have been postulated to mediate the low BMD seen after
BMT, including glucocorticoid use, chemotherapy, ir-
radiation, hypogonadism, decreased activity levels, and
chronic graft versus host disease [29]. Prior studies sup-
port our findings, demonstrating that BMT during child-
hood increases the risk of low BMD and fracture [29,30],
and that bone formation is decreased and bone resorp-
tion is increased in the months immediately following
BMT [31].
Our multivariate analysis demonstrated that 25OHD
insufficiency (< 30 ng/mL) is associated with a nearly 4-
fold increased risk of low BMD. This finding is consist-
ent with the observation of Cheng et al. demonstrating
that low 25OHD levels correlate with lower cortical
BMD in pre-pubertal and pubertal girls [32]. Unlike
many of the underlying medical conditions included in
our analysis, 25OHD insufficiency may be improved
with 25OHD supplementation and thus represents an
area amenable to intervention for improved bone health
in children and adolescents. Our selection of values less
than 30 ng/mL for defining 25OHD deficiency was
based upon the lower limit of the normal range of our
hospital laboratory. After we designed and initiated our
study, the Institute of Medicine reported on dietary
reference intakes for calcium and 25OHD, and con-
cluded that an adequate 25OHD level is≥ 20 ng/mL
[33]. However, controversy regarding adequate serum
25OHD levels remains (e.g., above 20 or 30 ng/mL or
higher) [34] and additional research is needed to identify
the optimal therapeutic target.
We found that low BMI is a significant risk factor for
low BMD, yet despite the robust relationship between
underweight and low BMD, we did not find a relation-
ship between malnutrition and low bone density. Prior
studies have demonstrated a strong relationship between
malnutrition in young women with anorexia nervosa, a
model of malnutrition-induced bone loss, and low BMD
[35-37], which we did not observe in this sample. Bone
density in these patients can vary depending on weight
loss or gain, and severity of disease. The patients with
anorexia nervosa included in this study could have
represented a skewed subgroup, with less severe disease
and bone loss. A prospective study of larger sample size
would likely be powered to reveal the expected relation-
ship between malnutrition and low BMD.
The multivariate analysis demonstrated that low height
Z-score is a risk factor for low BMD. Any child with an
underlying health problem may have short stature, con-
founding bone density measurements obtained by DXA
[38]. It is important to recognize that DXA measure-
ments may be confounded by bone size, an important
issue to consider when studying small underweight
adolescents with anorexia nervosa or other pediatric
chronic diseases [23]. Zemel et al. recently proposed
a method for height adjustment in calculating DXA
measurements of bone mass in growing children [39]
which will be useful to account for the effect of stat-
ure on BMD measurement. Despite these limitations
in smaller children, our findings suggest that children
who are underweight may be at risk for decreased
BMD.
Consistent with prior reports of gender differences in
fracture risk [40,41], we found that fractures occurred in
a higher percentage of boys than girls in a population re-
ferred for DXA measurement. This gender difference
has been attributed to higher rates of sports-related in-
juries in boys [40,41]. Surprisingly, in our univariate ana-
lysis of factors associated with BMD Z-score ≤-2 ,w e
found that male gender was a risk factor for low BMD.
This finding is questionable, as there is a known associ-
ation between male gender and higher BMD [42], and as
gender is no longer predictive in the multivariate model,
there may be other confounders influencing this finding.
As our subjects were selected from a retrospective sam-
ple of patients referred for DXA measurements, this ob-
servation may also represent selection bias and merits
further study.
Prior studies have demonstrated that IBD is both asso-
ciated with bone loss [43-45], and increased fracture risk in
adults [46]. Thus, the finding that a history of malabsorp-
tion or IBD was associated with decreased risk of low BMD
in the univariate and multivariate analyses was unexpected.
The retrospective design of our study may have introduced
bias, or referral bias may have influenced the selection of
subjects with IBD referred for DXA. Additionally, the tim-
ing of the BMD measurements in relation to the IBD
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have contributed to this finding.
Limitations of this study should be acknowledged. The
study design was a retrospective cohort study; therefore,
the findings represent associations and causality cannot
be inferred. Our results are limited by information
obtained solely from subjects referred for DXA measure-
ments at a tertiary care medical center. However, DXA
is the assessment tool used most commonly in clinical
practice around the world for bone density measure-
ments in children and adults. Thus, we are hopeful that
the information gleaned will be useful for clinicians, and
in particular, experts in bone health. Measurements of
volumetric BMD of the peripheral skeleton were not
available and would be valuable to obtain, especially in a
cohort of young patients, although this tool is only infre-
quently used at the present time for clinical purposes. By
design, our study was not able to include or identify sub-
jects who were not able to have DXA measurements
performed. The retrospective nature of our study
required us to rely upon diagnoses and referrals made
by providers and the samples sizes in many diagnostic
categories were small, limiting our ability to detect dif-
ferences in BMD. Additionally, due to the reliance on
the medical record, we were not able to include assess-
ments of physical activity. We acknowledge that physical
activity data would have been useful, as exercise may
positively impact BMD [18] and chronic disease often
limits activity for a child or adolescent. Obtaining an ac-
curate family history of osteoporosis was also limited by
the retrospective nature of this study, as some charts did
not include documentation of this information. How-
ever, despite these limitations, our results identified the
relative risks of a variety of medical conditions known to
be associated with low BMD in a sample of patients re-
ferred for DXA at a tertiary care center. The information
gained from our study highlights pediatric populations
who may be at highest risk for a low BMD and may be
candidates for bone density screening.
Conclusions
We used a novel approach to identify factors which lead
to the highest risk of low BMD in a pediatric cohort re-
ferred for DXA. Prior studies have focused on BMD in
specific populations, such as children and young adults
with a particular diagnosis or those receiving a certain
therapy. Our findings suggest that for all children re-
ferred for DXA, a low BMI Z-score, a history of BMT,
and vitamin D insufficiency are significant risk factors
for a low BMD. Identification of the medical conditions
and therapies that lead to the greatest risk of low BMD
in a pediatric population is especially important, given
that adequate bone mineral accretion during childhood
may impact the peak bone mass that is achieved during
adulthood, especially for children with chronic medical
conditions or therapies. Additionally, we hope that this
information can be used to help decrease the frequency
of fragility fractures in hospitalized children. Earlier
identification of risk factors could potentially lead to the
initiation of strategies that maximize bone health during
childhood and adolescence and ultimately reduce the fu-
ture risk for developing osteoporosis.
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